Sort   by:  
 Page size 
ProteomicsSelective inhibitors of JAK1 targeting a subtype-restricted allosteric cysteine
The JAK family of non-receptor tyrosine kinases includes four subtypes (JAK1, JAK2, JAK3, and TYK2) and is responsible for signal transduction downstream of diverse cytokine receptors. JAK inhibitors have emerged as important therapies for immuno(onc)ological disorders, but their use is limited by u...
ORGANISM(S): Homo sapiens (Human) Mus musculus (Mouse) 
2023-07-20 | PXD031384 | Pride
Abpp Pbmc Cysteine Allosteric Splenocyte Kinase Jak1 inhibitor 
ModelsSobotta2017 - IL-6-induced JAK1-STAT3-signaling
Here we present a mathematical model of IL-6-induced JAK1-STAT3 signaling that quantitatively links physiological IL-6 concentrations to the dynamics of IL-6-induced signal transduction and expression of target genes in hepatocytes. The mathematical model consists of coupled ordinary differential eq...
2023-07-05 | MODEL2307050001 | BioModels
TranscriptomicsTranscription profiling of human JAK1 wild-type and JAK1 mutation-positive T cell acute lymphoblastic leukemia blasts
Aberrant signal transduction contributes substantially to leukemogenesis. The Janus kinase 1 (JAK1) gene encodes a cytoplasmic tyrosine kinase that noncovalently associates with a variety of cytokine receptors and plays a nonredundant role in lymphoid cell precursor proliferation, survival, and diff...
ORGANISM(S): Homo sapiens 
2009-10-02 | E-GEOD-18239 | biostudies-arrayexpress
TranscriptomicsGene expression profiling upon knockdown of JAK1 in IM9 cells
Natural Killer (NK) cells are primary effectors of innate immunity directed against transformed cells. In response, tumor cells have developed mechanisms to evade NK cell-mediated lysis but the molecular basis for target cell resistance is not well understood. In the present study, we used a lentivi...
ORGANISM(S): Homo sapiens 
2012-06-27 | E-GEOD-37012 | biostudies-arrayexpress
TranscriptomicsRNA-seq of human leukemia cell lines, MHH-CALL-4 and MUTZ-5, treated either with Ruxolitinib, FX1, or their combination.
CRLF2-rearranged acute lymphoblastic leukemia (ALL) is associated with poor clinical outcomes. Although JAK1/2 is activated in this type of ALL, treatment with JAK1/2 inhibitors is insufficient in inhibiting cell growth and inducing apoptosis. BCL6 upregulation upon JAK inhibition may account for th...
ORGANISM(S): Homo sapiens 
2022-07-31 | E-MTAB-10755 | biostudies-arrayexpress
GenomicsRational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin
PRJNA979262 | ENA
GenomicsEffect of JAK1/2 Inhibitor treatment on beta cells from mice fed on high fat diet
Effect of JAK1/2 Inhibitor treatment on beta cells from mice fed on high fat diet
PRJNA1251888 | ENA
GenomicsJAK1/2 inhibitor therapy-associated lymphomas in myelofibrosis arising from a pre-existing B-cell clone
JAK1/2 inhibitor therapy-associated lymphomas in myelofibrosis arising from a pre-existing B-cell clone
PRJNA433197 | ENA
UnknownGSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis.
Not available
S-EPMC5624036 | biostudies-literature
UnknownJAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis.
Not available
S-EPMC9208297 | biostudies-literature
Sort   by:  
 Page size